DSM licenses Medi Vas' delivery platform

Dutch firm Royal DSM has obtained an exclusive worldwide license for a unique drug and biologic delivery system from the USA's MediVas, for its  Trancerta drug-delivery platform.

The technology is based on a next-generation set of biodegradable,  biocompatible and bioabsorbable polymers that are non-inflammatory and  allow greater control over the rate and duration of release of their  therapeutic payload.

The system can be used with a diverse group of drug candidates, from  proteins, peptides and nucleic acids to small-molecule drugs, thus  expanding the possible application areas of platform. The license DSM  obtained applies for the development of drug-delivery systems aimed at  treating ophthalmic, vascular and musculoskeletal diseases and at  providing general pain relief. MediVas will focus its development  efforts on nanoparticle-based therapies in oncology, immunology and on  the delivery of nucleic acids.